Bibliogragie:

1. Cristiana Glavce .Specificul patologiei cognitive din perspectivă antropologică a

pacienților vârstnici afectati de boli cardiovasculare. București 2007(pp6-7)
2. Gazzaley, A., Clapp, W., Kelley, J., McEvoy, K., Knight, R.T., D’Esposito, M.
(2008). Age-related top-down suppression deficit in the early stages of cortical visual
memory processing..Proceedings of the National Academy of Sciences, 105 (35),
13122-13126
3. Glisky, E.L. (2007). Changes in cognitive function in human aging. In D.R. Riddle,

(Ed.). (2007). Brain aging: Models, methods, mechanisms (pp. 1-15)


4. Boca Raton, FL: CRC Press. Retrieved July 30, 2009 from
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=frbrainage&part=ch1
5.Morrison, J.H., & Hof, P.R. (1997). Life and death of neurons in the aging brain.
Science, 278 (5337), 412-419
6. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive
impairment with and without dementia in an elderly population. Lancet. 1997;
349:1793-179
7.Petersen RC, Roberts RO, Knopman D, et al. Mild cognitive impairment: ten years
later. Arch Neurol 2009; 66:1447-55.
8. Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962;
86: 257–60
9. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current
nosological status .Lancet 2000; 355: 225–8
10. Graham JE, Rockwood K, Beattie BL et al. Prevalence and severity of cognitive
impairment with and without dementia in an elderly population. Lancet 1997; 349:
1793–6.
11. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence
but not outcomes of mild cognitive impairment. Neurology 2003; 61: 1179–84.
12. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with
limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;
133:540-56.
13. Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive
impairment. Arch Neurol 2001; 58: 1985–92
14. Busse A, Hensel A, Guhne U, Anger- meyer MC, Riedel-Heller SG. Mild cogni-
tive impairment: long-term course of four clinical subtypes. Neurology 2006;67: 2176-
85
15. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive
impairment is higher in men: the Mayo Ro Clinic Study of Aging. Neurology 2010;75:
tit 889-97
16. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild
cognitive impairment to dementia in clinic vs. community-based cohorts. Arch Neurol
2009; 66:1151-7
17. Uverzag FW, Gao S, Baiywu O, et al. Prevalence of cognitive impairment .Data
from the Indianapolish study of health and Aging .Neurology.2001 nov 13
18. Robert Ro, Geda YE,Knopman DS, et al. The Mayo study of Aging :design and
sampling participation , baseline measures and sample characteristic.
Neuroepidemiology .2008.30(1):58-69
19. Manly JJ, Tang MX, Schupf N, Stern Y, et Vonsattel JP, Mayeux R. Frequency
Course of mild cognitive impairment in a by multiethnic community. Ann Neurol 2008;
ro 63:494-506
20. Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the Short Test of
Mental Status and the Mini-Mental State Examination in mild cognitive impairment.
Arch Neurol 2003;60:1777-81.
21. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assess-
ment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc
2005;53:695-9.
22. Buschke H ,Fuld PA .Evaluating storage, retention, and retrieval in disordered
memory and learning. Neurology 1974;241019- 1025
23. Folstein MF,McHugh PR, “Mini-Mental State”: a practical method for grading the
cognitive state of patients for the clinician. J Psychiatr Res 1975;12189
24. Landau SM,Harvey D, Madiscon CM, Reiman EM,et al. Comparing predictors of
conversion and decline in mild cognitive impairment. Neurology.2010 Jul 75(3):230-8
25. Risarcher SL,Saykin AJ,West DJ et al.Disease Neuroimaging
Initiative(ADNI)Baseline MRI prediction of conversion from MCI to probable AD in the
ADNI cohort. Current Alzheimer Research.2009 Aug.6(4):347-61.
26. Pangman, VC; Sloan, J; Guse, L. (2000). "An Examination of Psychometric
Properties of the Mini-Mental Status Examination and the Standardized Mini-Mental
Status Examination: Implications for Clinical Practice". Applied Nursing Research. 13
(4): 209–213
27. Tuijl JP; Scholte EM, Van der Mast, RC (2012). "Screening for cognitive
impairment in older general hospital patients: comparison of the six-item cognitive
test with the Mini-Mental Status Examination". International journal of Geriatric
Psychiatry. 27: 755–762
28. Mungas D (July 1991). "In-office mental status testing: a practical guide".
Geriatrics. 46 (7): 54–8, 63, 66.
29. Palmqvist S.,Hansson O. Minthon L. ,Londos E. (December 2009). "Practical
suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's
disease with common cognitive tests.". International journal of geriatric psychiatry. 24
(12): 1405–12
30. Jefferson AL.; Cosentino S.A,Bogdanoff B, Leopold N, Kaplan E, Libon DJ,
( 2002). "Errors produced on the mini-mental status examination and
neuropsychological test performance in Alzheimer's disease, ischemic vascular
dementia, and Parkinson's disease.". The Journal of neuropsychiatry and clinical
neurosciences. 14 (3): 311–20.
31. Ala, TA; Hughes, LF; Kyrouac, GA; Ghobrial, MW; Elble, RJ (June 2002). "The
Mini-Mental Status exam may help in the differentiation of dementia with Lewy bodies
and Alzheimer's disease.". International journal of geriatric psychiatry. 17 (6): 503–9.
32. Arevalo-Rodriguez I.; Smailagic N.; Ciapponi A.; Sanchez-Perez E.; Giannakou
A.; Figuls M.; Cullum S. (2015). "Mini-Mental Status Examination (MMSE) for the
detection of Alzheimer's disease and other dementias in people with mild cognitive
impairment (MCI)". Cochrane Database of Systematic Reviews
33. Arevalo-Rodriguez I.; Smailagic N.; Ciapponi A.; Sanchez-Perez E.; Giannakou
A.; Figuls M.; Cullum S. (2015). "Mini-Mental Status Examination (MMSE) for the
detection of Alzheimer's disease and other dementias in people with mild cognitive
impairment (MCI)". URL : https://www.ncbi.nlm.nih.gov/pubmed/25740785
34. http://www.mocatest.org
35. Psychiatr Pol. 2016 Oct 31;50(5):1039-1052.
Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental
State Examination (MMSE) in mild cognitive impairment (MCI) detection among
people aged over 60? Meta-analysis.
Ciesielska N1, Sokołowski R1, Mazur E1, Podhorecka M1, Polak-Szabela A1,
Kędziora-Kornatowska K1
36. Scharre, Douglas W.; Chang, Shu-Ing; Murden, Robert A.; Lamb, James;
Beversdorf, David Q.; Kataki, Maria; Nagaraja, Haikady; Bornstein, Robert A. (2010-
01-01). "Self-administered Gerocognitive Examination (SAGE): A Brief Cognitive
Assessment Instrument for Mild Cognitive Impairment (MCI) and Early Dementia".
Alzheimer Disease & Associated Disorders. 24 (1): 64–71.
37. Cheng G, Huang C et al.- Diabetes as a risk factor for dementia and mild
cognitive impairment:a meta-analysis of longitudinal studies.Intern Med J . 2012 feb.
38. Jack CR Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic
mild cognitive impairment. Neurology 2008; 70:1740-52
39. Apostolova LG, Dutton RA, Dinov ID et al. Conversion of mild cognitive im-
pairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neu-
rol 2006;63:693-9. Erratum, Arch Neurol 2007; 64:1360-1.
40. . Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion
and decline in mild cognitive impair- ment. Neurology 2010;75:230-8
41. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild
cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's
disease Neurology 2003;60:1374-7
42. . Drzezga A, Grimmer T, Riemenschnei der M, et al. Prediction of individual clini-
cal outcome in MCI by means of genetic 2005 46:1625-32
43. Shaw LM, Vanderstichele H, Knapik- Czajka M, et al. Cerebrospinal fluid
biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann
Neurol 2009;65:403-13
44. Shin RW, Iwaki T, Kitamoto T, Tateishi J (May 1991). "Hydrated autoclave
pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's
disease brain tissues". Lab. Invest. 64 (5): 693–702
45. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's
disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-19.
46. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition
in patients with Alzheimer's disease. Brain 2006;129:2856-66.
47. Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive im pairment
subtypes. Ann Neurol 2009,65: 557-68
48. Association between CSF biomarkers, hippocampal volume and cognitive
function in patients with amnestic mild cognitive impairment (MCI)
Pradeep J. , Nathan , Yen Ying et al.Neurobiol Aging. 2017 Jan 18;53:1-10
49. Morris, J.C. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc
Disord. 2005; 19: 163–165
50. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr.,
Kawas, C.H. et al. The diagnosis of dementia due to Alzheimer's disease:
recommendations from the National Institute on Aging–Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement.
2011; 7: 263–269.
51. Lyketsos, C., Colenda, C., Beck, C., Blank, K., Doraiswamy, M., Kalunian, D. et
al. Position statement of the American Association for Geriatric Psychiatry regarding
principles of care for patients with dementia resulting from Alzheimer’s disease. Am J
Geriatr Psychiatry. 2006; 14: 561–572.
52. Bertram, L., Lill, C., and Tanzi, R. The genetics of Alzheimer disease: back to the
future. Neuron. 2010; 21: 270–281
53. Selkoe, D. Defining molecular targets to prevent Alzheimer’s disease. Arch
Neurol. 2005; 62: 192–195
54. Blennow, K. and Hampel, H. Cerebrospinal fluid markers for incipient Alzheimer’s
disease. Lancet Neurol. 2003; 2: 605–613
55. Shaw, L., Vanderstichele, H., Knapik-Czajka, M., Clark, C., Aisen, P., Petersen,
R. et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging
initiative subjects. Ann Neurol. 2009; 65: 403–413
56. Atiya, M., Hyman, B., Albert, M., and Killiany, R. Structural magnetic resonance
imaging in established and prodromal Alzheimer’s disease: a review. Alzheimer Dis
Assoc Disord. 2003; 17: 177–195
57. Kantarci, K. and Jack, C. Neuroimaging in Alzheimer’s disease: an evidenced-
based review.Neuroimaging Clin North Am. 2003; 13: 197–209
58. Dotson VM,Beydoun MA, Zonderman AB. Recurrent depressive symptoms and
the incidence of dementia and mild cognitive impairment. Neurology. 2010 jul 6.
75(1):27-34
59. Mild Cognitive Impairment in Parkinson’s Disease :Current Neurology and
Neuroscience Reports August 2011,Dag Aarsland ,Kolbjørn Brønnick
,Tormod Fladby,Volume 11, Issue 4, pp 371–378
60. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive
impairment in Parkinson’s disease: progression to dementia. Mov Disord. 2006
Sep;21(9):1343–9.
61. Blake J. Lawrence, Natalie Gasson,and Andrea M. Loftus. Prevalence and
Subtypes of Mild Cognitive Impairment in Parkinson’s Disease.Sci Rep. 2016; 6:
33929.Published online 2016 Sep 21
62. Sasaki NFukatsu RTsuzuki K et al. Advanced glycation end products in
Alzheimer's disease and other neurodegenerative diseases. Am J
Pathol1998;1531149- 1155
63. Erkinjuntti T: Cerebrovascular dementia: pathophysiology, diagnosis and
treatment. CNS Drugs12 :35 –46,1999
64. Sprung J ,Roberts Ro et al. Association of Mild Cognitive Impairment with
exposure to General Anesthesia for Surgicam and Nonsurgical Procedures:A
population- based study. Mayo Clinic Proc. 2016 Jan 2
65. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diag-
nosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Lancet Neurol 2007;6:501-12.
66. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in sub-
jects with mild cognitive impairment. Neurology 2008;70:2024-35
67. Petersen RC, Thomas RG, Grundman f M, et al. Vitamin E and donepezil for the
treatment of mild cognitive impairment. 1 N Engl JMed 2005; 352:2379-88.
68. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu
XG, Chui D, Liu G (2014). "Elevation of brain magnesium prevents synaptic loss and
reverses cognitive deficits in Alzheimer's disease mouse model". Molecular
Brain. 7 (65): 1–20.
69. Veronese N, Zurlo A, Solmi M, Luchini C, Trevisan C, Bano G, Manzato E, Sergi
G, Rylander R (2016). "Magnesium Status in Alzheimer's Disease: A Systematic
Review". American journal of Alzheimer's disease and other dementias. 31 (3): 208–
213.
70. McCaddon,A.; et al. (2001)."Homocysteine and cognitive decline in healthy
elderly". Dement Geriatric Cognitive Disorder. 12 (5): 309–313
71. Jean L, Ecrgeron ME. Tliivierge , Sinurd M. Cognitive intervention programs
forindividuals wirh mild cognitive impairment: sysremaric review of the literature.Am J
Geriarr Psychiatry 2010;18:281-96
72. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild conitive
impairment in clinical care: a survey of American Academy of Neurology members.
Neurology 2010,75: 425-31